Protective effect of whey proteins against nonalcoholic fatty liver in rats by Essam M Hamad et al.
RESEARCH Open Access
Protective effect of whey proteins against
nonalcoholic fatty liver in rats
Essam M Hamad1, Soad H Taha1, Abdel-Gawad I Abou Dawood1, Mahmoud Z Sitohy2 and
Mahmoud Abdel-Hamid1*
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and
can vary from hepatic steatosis to end-stage liver disease. It is the most common liver disease and its prevalence is
increasing worldwide. In the present study, the effect of whey proteins on some parameters of NAFLD was
investigated.
Results: Oral administration of the studied whey proteins products reduced the final body weight of rats. There
was a significant reduction effect (P < 0.05) of the tested proteins on hepatic triglycerides, liver enzymes (ALT and
AST), lipid peroxidation (malondialdehyde level) and serum glucose. Feeding on whey proteins caused an increase
in the reduced glutathione. Hepatic content of reduced glutathione was not affected by any of the used whey
proteins, but it showed an increasing tendency (P > 0.05). Liver histology showed an improvement of fatty
infiltration in hepatocytes from whey protein groups and gives the histology of liver a normal appearance.
Conclusions: The obtained results indicate a possible role for oral administration of whey proteins in the
regulation of liver biochemistries in a rat’s model of NAFLD. This regulatory effect of whey proteins was
accompanied by an improvement in fatty infiltration in hepatocytes and a reduction of oxidative stress parameters.
Background
Nonalcoholic fatty liver disease (NAFLD) is a wide
spectrum of fatty liver changes ranging from hepatic
steatosis (i.e. abnormal retention of lipids within a cell)
to steatohepatitis (nonalcoholic steatohepatitis), which
can progress to liver fibrosis and cirrhosis in the
absence of alcohol consumption. NAFLD is rapidly
becoming a worldwide public health problem. It is
present in 10-24% of the world’s population and its pre-
valence is even greater in obese individuals, ranging
from 57.5 to 74.0% [1]. In Egypt, its prevalence in the
morbidly obese population has been estimated as 22%
for male and 48% for female [2]. Evidence from human
studies and animal models have suggested that lipid
accumulation in the liver (fatty liver) plays an important
role in the pathogenesis of heart failure, obesity, diabetes
and metabolic syndrome [3]. Treatment strategies for
NAFLD aim to improve insulin sensitivity and modify
metabolic risk factors, or protect the liver from oxidative
stress. Therefore, the discovery of nutrients that amelio-
rate fatty liver is of interest.
Whey proteins (WP) represent a heterogeneous group
of proteins (b-lactoglobulin, a-lactalbumin, serum
albumin, immunoglobulins ...etc.). It has been suggested
that WP has an antioxidant activity probably depending
on the abundance of cysteine in WP or on the presence
of glutamylcysteine groups which are in other food pro-
teins. Therefore, WP may be considered as a possible
therapeutical tool in oxidative stress correlated diseases
[4]. An undenatured cysteine-rich whey protein isolate
(WPI) has been proven to raise glutathione levels by
supplying the precursors required for intracellular
glutathione synthesis. This has been demonstrated in
several glutathione-deficient patient groups including
those with advanced human immunodeficiency virus
(HIV) infection [5]. Whey protein concentrate (WPC),
beta-lactoglobulin and alpha-lactalbumin improve the
liver damage induced by CCl4 [4,6]. Oral administration
of colostrum, which contains high amount of whey
proteins, significantly decreased total cholesterol and tri-
glycerides (TG) levels in both the men and women after
* Correspondence: mahmoudah3@yahoo.com
1Dairy Science Department, Faculty of Agriculture, Cairo University, Egypt
Full list of author information is available at the end of the article
Hamad et al. Lipids in Health and Disease 2011, 10:57
http://www.lipidworld.com/content/10/1/57
© 2011 Hamad et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
4 weeks [7]. Few studies used total whey proteins or
WPI to study their effect on fatty liver [8,9]. Hence, this
study aimed to investigate the protective effect of oral
administration of different WP products against fatty
liver in an experimental rat model.
Results
Growth parameters
Effect of oral administration of whey proteins on growth
parameters of rats is presented in Table 1. Initial body
weight of all rats was 138.8 ± 18.1 g. Non significant dif-
ferences were found between body weight control rats
and rats fed on high carbohydrate, fat free (HCFFD)
diets (P > 0.05).
Whey protein hydrolysate (WPH) and glycomacropep-
tide (GMP) rat groups also showed insignificant reduc-
tion in the final body weight of rats (P > 0.05). However,
final body weight of rats decreased significantly when
they were given whey protein isolate (WPI), a-lactalbu-
min or b-lactoglobulin.
Furthermore, liver weight of rats fed on control diet
was similar to that of HCFFD rat group (P > 0.05).
Compared with steatosis group (HCFFD), oral adminis-
tration of WPI significantly (P < 0.05) decreased liver
weight of rats, while the other whey proteins had non
significant effect on the liver weight (P > 0.05). All the
studied whey proteins had no significant effect on the
hepatic index.
Blood glucose and cholesterol and tissue triglycerides
Effect of oral administration of different whey proteins
products on blood glucose and cholesterol and tissue
triglycerides is presented in Table 2. Feeding rats on
HCFFD was associated with a significant elevation of
their blood glucose levels (76% elevation, P < 0.001) as
compared with control diet group. It also appeared that
oral administration of all the tested whey proteins
lowered the blood glucose levels of rats, except for the
a-Lactalbumin (aLA) group in which no significant
difference was found as compared to the HCFFD
group. Lowest levels of blood glucose were observed
when rats were fed either WPI (86.69 ± 5.27 mg/dL)
or GMP (95.02 ± 10.40 mg/dL) in which the levels of
blood glucose were comparable with the control group
(P > 0.05).
The serum total cholesterol level of the HCFFD group
tended to be higher (P > 0.05) than that of the control
group. The lowest serum cholesterol level was obtained
when rats were given the aLA (51.72 ± 4.75 mg/dL). It
was also significantly different from that of HCFFD
group (P < 0.05). The other whey proteins did not show
any significant lowering effect on the serum total choles-
terol of rats (Table 2).
The liver content of triglycerides (TG) is presented in
Table 2. HCFFD group was characterized by its higher
TG content (P < 0.001) as compared with that in the
control diet. All the tested whey proteins showed a
significant lowering effect on the liver content of TG
compared with both the control and the HCFFD rat
groups (P < 0.05). The lowest TG content was observed
when rats were fed on WPH which was about 67% and
79% lower than that of the control and HCFFD groups,
respectively.
Serum alanine transaminase (ALT) and aspartate
transaminase (AST)
Figure 1 illustrates the data of serum alanine transami-
nase (ALT) and aspartate transaminase (AST) as
affected by the administration of whey proteins. The
levels of ALT and AST increased significantly when rats
were fed on HCFFD (P < 0.05) as compared with the
Table 1 Effect of oral administration of whey proteins
products on final body weight, liver weight and hepatic
index of rats fed the normal (control) and high
carbohydrate, fat free (HCFFD) diets
Final body weight (g) Liver weight (g) Hepatic Index
Control 180.32 ± 21.66 a 6.27 ± 1.24ab 3.65 ± 0.73a
HCFFD 158.10 ± 25.77 ab 6.53 ± 1.27a 3.96 ± 0.35a
WPI 126.48 ± 18.90b 4.22 ± 0.99b 3.32 ± 0.50a
WPH 131.70 ± 13.79ab 4.30 ± 1.62ab 3.25 ± 0.45a
aLA 128.76 ± 22.88b 4.67 ± 0.85ab 3.66 ± 0.60a
bLG 121.07 ± 8.13b 4.53 ± 0.33 ab 3.74 ± 0.12a
GMP 155.19 ± 19.07ab 5.98 ± 1.15ab 3.85 ± 0.49a
Mean values with their standard deviation for five rats per group
WPI: whey protein isolate, WPH: whey protein hydrolysate, aLA: alpha
lactalbumin, bLG: Beta lactoglobulin, GMP: glycomacropeptide.
Means in a column without common letter are significantly differ, P < 0.05
(Tukey’s test).
Table 2 Effect of oral administration of whey proteins
products on serum glucose and total cholesterol and
on liver triglycerides of rats fed the normal and high







Control 86.69 ± 5.27d 71.92 ± 5.82ab 8.27 ± 1.08b
HCFFD 152.76 ± 20.81a 79.19 ± 9.85a 12.39 ± 2.32a
WPI 102.74 ± 10.96cd 69.29 ± 4.48ab 3.71 ± 1.64c
WPH 118.92 ± 10.61bc 63.74 ± 5.50ab 2.54 ± 0.31c
aLA 130.21 ± 16.95ab 51.72 ± 4.75b 3.07 ± 0.78c
bLG 115.06 ± 11.73bc 76.64 ± 7.47ab 2.58 ± 0.90c
GMP 95.02 ± 10.40cd 58.43 ± 6.55ab 2.59 ± 0.94c
Mean values with their standard deviation for five rats per group
WPI: whey protein isolate, WPH: whey protein hydrolysate, aLA: alpha
lactalbumin, bLG: Beta lactoglobulin, GMP: glycomacropeptide, TG:
triglyceride.
Means in a column without common letter significantly differ, P < 0.05
(Tukey’s test).
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control group. Oral administration of whey proteins
under the present study lowered the serum levels of
both enzymes to be in the range of the control group
(P > 0.05). The lowest level of ALT was obtained when
rats were fed on aLA (20.49 ± 10.0 U/L), while the low-
est level of AST was observed when rats were given
WPI (15.35 ± 5.46 U/L).
Lipid peroxidation and oxidative stress
Data in Table 3 show the effect of whey proteins pro-
ducts on lipid peroxidation (malondialdehyde; MDA)
and oxidative stress (reduced glutathione; GSH). It can
be observed that MDA was significantly elevated in the
HCFFD group as compared to the control group (P <
0.05). Feeding rats whey proteins was accompanied by
lower MDA levels (P < 0.05), except for GMP group in
which non significant differences were found between
MDA levels and that of HCFFD group. On the contrary,
GSH levels showed a tendency to be lower in the
HCFFD group compared with the control (P > 0.05).
Oral administration of WPI, WPH and bLG elevated the
GSH levels significantly (P < 0.05, compared with
HCFFD) while the rest of the whey proteins showed
similar levels to the control.
Histological examination
The histological examination of livers from the experi-
mental rat groups is shown in Figure 2. It can be
noticed that appearance of the liver from the control
group was normal, and hepatocytes of this group exhib-
ited normal morphology. On contrast, the appearance of
the HCFFD group was looking like the fatty liver. Also,
fatty infiltration and the fat vacuoles were found in
more than 66% of hepatocytes macrovesicular vacuoles.
Oral administration of whey proteins products showed
a positive effect on the histological examination of livers.
The livers of all whey protein groups were improved
and appeared with less fatty infiltration of hepatocytes
as compared with HCFFD group (Figure 2).
Discussion
Nonalcoholic fatty liver disease (NAFLD) occurs across
all age groups and occurs in 14%-30% of the general
population [10]. In this study, whey proteins products
were assessed for their ability to improve the biochem-
ical and histological features of disease activity in
NAFLD induced by a high carbohydrate fat free diet in
Wistar rats. Recently, few studies were concerned with
the effect of whey proteins on the parameters of fatty
liver [8,9]. Most of these studies focused on the use of
total whey proteins instead of using their fractions indi-
vidually. After 4 weeks of feeding high carbohydrate fat
free diet, the histological appearance (Figure 2) of the
positive control group (HCFFD) showed a typical
appearance of fatty liver as reported by [11]. All tested
whey proteins products led to an improvement in
the results of histological examination of their livers






































Figure 1 Effect of oral administration of whey proteins
products on serum alanine transaminase (ALT) and aspartate
transaminase (AST) in rats fed the normal and high
carbohydrate, fat free diets.
Table 3 Effect of oral administration of whey proteins
products on malondialdehyde and reduced glutathione






Control 220.33 ± 3.65b 91.58 ± 7.33ab
HCFFD 549.48 ± 7.99a 69.57 ± 8.37b
WPI 280.37 ± 1.42b 117.42 ± 5.50a
WPH 230.36 ± 7.45b 125.78 ± 3.56a
aLA 227.31 ± 6.12b 110.82 ± 4.92ab
bLG 229.99 ± 2.81b 115.27 ± 1.91a
GMP 365.56 ± 9.40ab 109.49 ± 2.70ab
Mean values with their standard deviation for five rats per group
WPI: whey protein isolate, WPH: whey protein hydrolysate, aLA: alpha
lactalbumin, bLG: Beta lactoglobulin, GMP: glycomacropeptide.
Means in a column without common letter significantly differ, P < 0.05
(Tukey’s test).
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and ALT levels were improved in all whey protein
groups. Further more, oral administration of all whey
proteins products improved malondialdehyde levels.
In the current study, the growth parameters observa-
tion showed a reduction in the final body weight with
oral administration of some whey proteins. These results
are consistent with a variety of epidemiological trials
whereas whey proteins or dairy products enhanced
weight and fat mass loss in humans and animals [12,13].
However, not all weight loss studies were in agreement
with this conclusion [14]. Therefore, the results of the
current study confirm that oral administration of whey
proteins may reduce weight gain in rats.
The key factor in nonalcoholic fatty liver disease is
insulin resistance. Recent data clearly implicate hepatic
insulin resistance as a responsible factor for the accu-
mulation of free fatty acids as triglycerides in hepato-






Figure 2 Effect of oral administration of whey proteins products on the histological examination of livers from rats fed high
carbohydrate, fat free diet for 4 weeks. Control; basal diet group, WPI; whey protein isolate group, WPH; whey protein hydrolysate group,
aLA; alpha lactalbumin group, bLG; beta lactoglobulin group and GMP; glycomacropeptide group. Arrows show numerous spherical vacuoles of
fat droplets.
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disease, at present, are primarily focused on weight loss
and use of insulin sensitizing agents [15]. In this study,
oral administration of all the tested whey proteins
reduced serum glucose levels. At the same time, this
beneficial effect was associated with a reduction in the
hepatic triglycerides. Consequently, the histology of the
livers of all whey protein groups appeared with less fatty
infiltration in hepatocytes (Figure 2). This effect is simi-
lar to that observed by [8] who found that whey + cal-
cium containing diet significantly decreased blood
glucose, serum insulin, and hepatic triglycerides in lean
and obese C57Bl/6J mice.
In addition, alanine transaminase (ALT) is an impor-
tant enzyme found predominately in the liver. Signifi-
cantly elevated activity of ALT in serum often suggests
its leakage from damaged hepatic cells and reflects
hepatocyte damage. Aspartate aminotransferase (AST) is
similar to ALT in that it is another enzyme associated
with liver. The ALT is a more specific indicator of liver
inflammation than the AST, as the AST may also be
elevated in diseases affecting other organs. For this rea-
son, ALT is commonly used as a way of screening for
liver problems. Elevated ALT levels correlated strongly
with NAFLD [16,17]. In the present study, oral feeding
of whey proteins lowered levels of ALT and AST in rats’
model of fatty liver (Figure 1). This positive effect on
ALT and AST might account for the improvement of
the liver histology and less fatty infiltration in hepato-
cytes. These findings are in agreement with [9], who
reported that a daily dose of 20 g whey protein isolate
for 12 weeks given to fatty liver patients led to a signifi-
cant reduction in ALT and AST.
Mitochondrial dysfunction is thought to play a central
role in NLFLD as production of reactive oxygen species
is increased and lead to inflammation, hepatocellular
apoptosis, or in other words increased oxidative stress
[9]. Hepatocyte and plasma glutathione (reduced form,
GSH) decreased and glutathione disulfide (oxidized form,
GSSG) increased in NAFLD patients [18]. As a conse-
quence, strategies to increase glutathione concentrations
to reduce oxidative stress might play an important role in
pathogenesis of NAFLD. In the results of our study, a sig-
nificant elevation in the GSH content was observed only
when rats were fed on WPI, WPH or bLG (P < 0.05,
compared with HCFFD). An undenatured cysteine-rich
whey protein isolate has been proven to raise glutathione
levels by supplying the precursors required for intracellu-
lar glutathione in several glutathione-deficient patient
groups including those with advanced human immuno-
deficiency virus (HIV)-infection [19]. Also, total milk
proteins did not decrease total liver GSH compared with
the high sucrose diet group [20].
In addition, lipid peroxidation leads to the generation
of by-products, such as malondialdehyde (MDA), which
are involved in activation of the inflammatory response
and consequently, cellular damage [19]. The results of
high hepatic MDA levels in the steatosis group are in
agreement with the results of [17]. Oral administration
of whey proteins products was associated with lowering
content of MDA in liver (Table 3). It is expected that
the potential effect of whey proteins in preventing
further accumulation of free radicals as well as oxidative
stress could be due to their anti oxidant capacity and/or
their anti-inflammatory effect. Previously, it was
observed that whey protein led to an increase in the
antioxidant enzymes and a decrease in the oxidative
stress. Whey proteins also showed an anti-inflammatory
effect in humans [21,22].
Oral administration of some whey proteins products
(specially WPH and WPI) improved the fatty liver state
in a rat model of NAFLD, which is in correlation with
the results of histological examination of rats’ liver and
a reduction in hepatic triglycerides, liver enzymes levels
(ALT and AST), serum glucose and lipid peroxidation
(MDA). Further studies are needed to give further
insight into the underlying mechanism.
Materials and methods
This study was approved by the Committee of Scientific
Ethics at Cairo University and according to its
guidelines.
Materials
Whey protein isolate (WPI), whey protein hydrolysate
(WPH), a-lactalbumin (a-LA), b-lactoglobulin (b-LG)
and glycomacropeptide (GMP) were kindly obtained
from Davisco Food International (USA).
Male Wistar rats of average weight 138.8g were
obtained from Animal House Lab., National Research
Center, Cairo, Egypt.
Basal diet: a balanced basal diet (30% sucrose, 35%
starch, 16% casein, 10% oil, 5% fiber and 4% minerals &
vitamins) was obtained from Meladco Company, Egypt.
High carbohydrate, fat-free diet (40% starch, 40%
sucrose, 16% casein and 4% minerals & vitamins) was
prepared at Dairy Science Department, Faculty of Agri-
culture, Cairo University.
Commercial diagnostic kits for the determination of:
serum glucose, activities of aspartate and alanine amino-
transferase (ALT&AST), total cholesterol (TC), liver tri-
glycerides, tissue malondialdehyde and tissue glutathione
were obtained from Biodiagnostic, Egypt. All other che-
micals used in this study were of analytical grade.
Methods
Experimental procedure
7 groups of male Wistar rats (5 rats each) were submitted
to the following treatments: group 1: negative control
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(rats were fed on the basal diet), group 2: positive control
rats were fed on high carbohydrate fat free diet (HCFFD)
to induce fatty liver according to [11], groups 3, 4, 5, 6
and 7; rats were fed on HCFFD and at the same time
orally administrated 0.15 g/day/rat of WPI, WPH, a-LA,
b -LG and GMP as a suspension in 2 ml water, respec-
tively [23]. After 28 days, animals were sacrificed and
blood samples were collected from retro-orbital venus
plexus from all animals in plain test tubes.
Biochemical marker
The activities of serum aspartate and alanine amino-
transferase (AST&ALT), serum glucose, total cholesterol
(TC), liver triglycerides (TG), glutathione and malon-
dialdehyde were measured using the colorimetric meth-
ods described in the kits from Biodiagnostic, Egypt.
Histological evaluation
After rats were sacrificed, their livers were weighed and
liver tissue samples were taken immediately and placed
in 10% buffered formalin and subsequently embedded in
paraffin. Hepatic index was obtained by dividing liver
weight by rat weight × 100. Liver sections were stained
with hematoxylin and eosin using standard techniques.
Fat accumulation in liver sections was observed as men-
tioned by [24].
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). Data were analyzed by one-way analysis of var-
iance (ANOVA), followed by assessment of differences
by Tukey’s post-hoc test. All statistical calculations were
performed using SPSS version 16.0 [25]. Results were
considered statistically significant at P < 0.05.
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